Kansai Electric Power (Japan)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Boehringer Ingelheim (Germany)德国2
2. Boehringer Ingelheim (Japan)日本2
3. Peking University People's Hospital中国1
4. Toranomon Hospital日本1
5. Tongji University中国1
6. Shimane University日本1
7. Kansai Electric Power Hospital日本1

按月发文

逐年被引

最新文献

1. 1
   Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety20220
2. 2
   Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsExpert Opinion on Drug Safety20213
3. 3
   Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluationExpert Opinion on Drug Safety201724
4. 4
   Alogliptin for the treatment of type 2 diabetes: a drug safety evaluationExpert Opinion on Drug Safety20156
5. 5
   Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse eventsExpert Opinion on Drug Safety201598

高被引文献

1. 1
   Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse eventsExpert Opinion on Drug Safety201598
2. 2
   Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluationExpert Opinion on Drug Safety201724
3. 3
   Alogliptin for the treatment of type 2 diabetes: a drug safety evaluationExpert Opinion on Drug Safety20156
4. 4
   Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsExpert Opinion on Drug Safety20213

主要发表期刊